# US 2020/0392176 A1 · Solid forms of (2s,3s,4s,5r,6s)-3,4,5-trihydroxy-6-(((4ar,10ar)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2h-pyran-2-carboxylic acid

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392176 A1
- Document ID: US20200392176A1
- Status: Published application
- Kind: A1
- Application number: 16/876,908
- Filed: 2020-05-18
- Published: 2020-12-17
- Earliest claimed: 2019-05-20
- Assignees: H. Lundbeck A/S
- Applicants: H. Lundbeck A/S
- Inventors: Klaus Gjervig Jensen; Lisbet Kværnø; Morten Jørgensen; Martin Juhl; Heidi Lopez de Diego; Karin Fredholt; Frans Dennis Therkelsen; Tobias Gylling Frihed; Mikkel Fogh Jacobsen
- Web page: https://patentgrep.com/patent/US20200392176A1

## CPC

- C07H 15/26: Acyclic or carbocyclic radicals, substituted by hetero rings
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention relates to new solid forms of the compound (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid with the formula (Id) below. The compound of formula (Id) is a prodrug of a catecholamine for use in treatment of neurodegenerative diseases and disorders such as Parkinson's Disease.

## Claims

### Claim 1

A solid form of the compound of formula (Id)
wherein said solid form is selected from:
a) a form of the zwitterion of compound (Id);
b) an alkali metal salt of the compound of formula (Id); and
c) a halogen salt of the compound of formula (Id).

### Claim 2 (depends on 1)

The solid form according to claim 1, wherein said solid form is a crystalline form.

### Claim 3 (depends on 1)

The solid form according to claim 1, wherein said solid form is selected from the group consisting of the dihydrate of the zwitterion of compound (Id), the heptahydrate of the zwitterion of compound (Id) and the potassium salt of the compound (Id).

### Claim 4 (depends on 1)

The solid form according to claim 1, wherein said solid form is the dihydrate of the zwitterion of compound (Id) or the potassium salt of the compound (Id).

### Claim 5 (depends on 1)

The solid form according to claim 1, wherein said solid form is the dihydrate characterized by an x-ray powder diffraction pattern as obtained using CuKα1 radiation (λ=1.5406 Å) comprising one or more XRPD peaks as listed for the dihydrate in Table 2, group (a).

### Claim 6 (depends on 1)

The solid form according to claim 1, wherein said solid form is the dihydrate characterized by an x-ray powder diffraction pattern as obtained using CuKα1 radiation (λ=1.5406 Å) comprising peaks at the following 2θ-angles±0.2° 2θ:10.4, 11.6, 12.3, 13.1, and 13.6°.

### Claim 7 (depends on 6)

The solid form according to claim 6, wherein said x-ray powder diffraction pattern further comprises one or more peaks selected from the group consisting of peaks at the following 2θ-angles±0.2° 2θ: 14.3, 15.6, 16.0, 16.8, and 18.5°.

### Claim 8 (depends on 1)

The solid form according to claim 1, wherein said solid form is a crystal form characterized by an x-ray powder diffraction pattern as obtained using CuKα1 radiation (λ=1.5406 Å) essentially as depicted in FIG. 8a.

### Claim 9 (depends on 1)

The solid form according to claim 1, said solid form exhibiting a weight loss of about 7.6% w/w compared to the initial weight when heated from about 30° C. to about 150° C. (heating rate 10° C./min).

### Claim 10 (depends on 1)

The solid form according to claim 1, wherein said solid form is the potassium salt characterized by an x-ray powder diffraction pattern as obtained using CuKα1 radiation (λ=1.5406 Å) comprising one or more XRPD peaks as listed for the potassium salt in Table 2, group (a).

### Claim 11 (depends on 10)

The solid form according to claim 10, wherein said potassium salt has a crystal form characterized by an XRPD obtained using CuKα1 radiation (λ=1.5406 Å) comprising peaks at the following 2θ-angles±0.2° 2θ: 3.0, 9.0, 12.6, 13.6, and 15.0°.

### Claim 12 (depends on 11)

The solid form according to claim 11, wherein said x-ray powder diffraction pattern further comprises one or more peaks selected from the group consisting of peaks at the following 2θ-angles±0.2° 2θ: 17.1, 18.0, 18.4, 18.8 and 19.4°.

### Claim 13 (depends on 1)

The solid form according to claim 1, said form exhibiting a weight loss of less than about 1% w/w compared to the initial weight when heated from about 20° C. to about 150° C. (heating rate 10° C./min.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of the solid form of the compound of formula (Id) according to claim 1, and one or more pharmaceutically acceptable excipients.

### Claim 16

(canceled)

### Claim 17 (depends on 1)

A method for the treatment of a neurodegenerative disease or disorder such as Parkinson's Disease, Huntington's disease, Restless leg syndrome or Alzheimer's disease; or a neuropsychiatric disease or disorder such as schizophrenia, attention deficit hyperactivity disorder or drug addiction; comprising the administration of a therapeutically effective amount of solid form of the compound of formula (Id) according to claim 1 to a patient in need thereof.

### Claim 18 (depends on 1)

A method for the manufacture of a medicament comprising combining a solid form of the compound of formula (Id) according to claim 1 with and one or more pharmaceutically acceptable excipients.
